Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children

BACKGROUND: Typhoid fever caused by multidrug-resistant H58 Salmonella Typhi is an increasing public-health threat in sub-Saharan Africa. We present phase 3 efficacy data from an African trial of a Vi-polysaccharide typhoid conjugate vaccine (Vi-TCV). METHODS: Children aged 9 months to 12 years in B...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Patel, Priyanka D., Patel, Pratiksha, Liang, Yuanyuan, Meiring, James E., Misiri, Theresa, Mwakiseghile, Felistas, Tracy, J. Kathleen, Masesa, Clemens, Msuku, Harrison, Banda, David, Mbewe, Maurice, Henrion, Marc, Adetunji, Fiyinfolu, Simiyu, Kenneth, Rotrosen, Elizabeth, Birkhold, Megan, Nampota, Nginache, Nyirenda, Osward M., Kotloff, Karen, Gmeiner, Markus, Dube, Queen, Kawalazira, Gift, Laurens, Matthew B., Heyderman, Robert S., Gordon, Melita A., Neuzil, Kathleen M.
Format: Artigo
Idioma:Inglês
Publicat: Massachusetts Medical Society 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202713/
https://ncbi.nlm.nih.gov/pubmed/34525285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2035916
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars